GC
ABBV icon

GatePass Capital’s AbbVie ABBV Stock Holding History

GatePass Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$994K Buy
3,951
+57
+1% +$12.3K 0.38% 68
2026
Q1 		$847K Buy
3,894
+26
+0.7% +$5.77K 0.4% 67
2025
Q4 		$884K Buy
3,868
+45
+1% +$10.3K 0.46% 53
2025
Q3 		$885K Buy
3,823
+19
+0.5% +$3.87K 0.51% 50
2025
Q2 		$706K Sell
3,804
-117
-3% -$21.7K 0.47% 54
2025
Q1 		$821K Buy
3,921
+20
+0.5% +$3.89K 0.62% 39
2024
Q4 		$693K Buy
+3,901
New +$717K 0.75% 33

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

GatePass Capital's ABBV Position: Q2 2026 in Review

GatePass Capital increased its AbbVie (ABBV) stake by 1.5% in Q2 2026, buying an estimated $12.3K and bringing the position to 3,951 shares worth $994K. The position accounts for 0.38% of the portfolio, ranked #68.

GatePass Capital first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • GatePass Capital held 3,951 shares of AbbVie worth $994K as of Q2 2026.
  • GatePass Capital bought 57 AbbVie shares in Q2 2026, an estimated $12.3K.
  • AbbVie made up 0.38% of GatePass Capital's portfolio in Q2 2026, its #68 holding.
  • GatePass Capital first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on GatePass Capital's 13F filing for Q2 2026, filed 30 Jul 2026.